MedTrace Logo

Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival

NCT07731425 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2026-07-28

No results posted yet for this study

Summary

This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs

Conditions

Interventions

OTHER

FDA explanation for progression-free survival (control)

Progression-free survival

OTHER

FDA explanation for progression-free survival with overall survival data

The description, 'progression-free survival', along with data on overall survival.

OTHER

NCI explanation for progression-free survival

The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse'.

OTHER

NCI explanation for progression-free survival with overall survival data

The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse', along with data on overall survival.

OTHER

Plain-language explanation of progression-free survival

The description, 'the length of time until a test showed the cancer grew, spread, or worsened'.

OTHER

Plain-language explanation of progression-free survival with overall survival data

The description, 'the length of time until a test showed the cancer grew, spread, or worsened', along with data on overall survival.

Sponsors & Collaborators

  • Harvard Medical School and Harvard Pilgrim Health Care Institute

    collaborator UNKNOWN

  • London School of Economics and Political Science

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2026-10-01
Completion
2026-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07731425 on ClinicalTrials.gov